Non-vesicular Nanoparticles for Microbial Infection Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for microbial infections, including antibiotic-resistant strains and fungal infections, face challenges such as rapid resistance development, side effects, and limited efficacy, necessitating the development of novel therapeutic agents that can effectively target microorganisms without inducing resistance.
Innovation Solution
A non-vesicular nanoparticle composed of fatty acids or their derivatives, surfactants, and optional lipids, specifically designed to target and inhibit a wide range of bacteria and fungi, including antibiotic-resistant strains, by forming stable micellar structures that maintain antibacterial activity and stability over time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum antibiotics are used to treat microbial infections, then the initial treatment effect is good, but drug resistance emerges rapidly
Solution Approach 1:
The patent changes the chemical structure parameters by introducing a novel nanocapsule formulation with specific components (phospholipids, cholesterol, surfactants) and ratios, creating a new delivery system that achieves antibacterial effects through a different mechanism than traditional antibiotics, thereby avoiding resistance development
Solution Approach 2:
The patent uses composite materials by combining multiple substances (phospholipids, cholesterol, surfactants, and active ingredients) into a nanocapsule structure, creating a complex delivery system that enhances efficacy and reduces resistance compared to single-agent antibiotics
2Reliability
If existing antibiotics are used to treat Helicobacter pylori infection, then the treatment can clear the infection, but resistance to antibiotics develops rapidly reducing eradication rates
Solution Approach 1:
The patent segments the treatment approach by using a nanocapsule delivery system that separately delivers multiple active ingredients (such as bismuth subcitrate, zinc gluconate, and herbal extracts) to the infection site, allowing each component to work synergistically while reducing individual resistance pressure
Solution Approach 2:
The nanocapsule structure acts as an intermediary delivery vehicle that protects active ingredients from degradation, controls their release at the infection site, and enhances their penetration into H. pylori biofilms, thereby improving eradication efficacy without increasing resistance
3Reliability
If vancomycin is used to treat MRSA, then the bacteria can be inhibited, but the bacteria cannot be eradicated and resistance continues to emerge
Solution Approach 1:
The patent utilizes phase transition properties by incorporating cholesterol and phospholipids that undergo phase changes at physiological temperatures, allowing the nanocapsule to maintain structural integrity in circulation while releasing active ingredients at the infection site, thereby achieving both inhibition and eradication of MRSA
Solution Approach 2:
The nanocapsule formulation is designed to be dynamic, adjusting its permeability and release rate in response to the bacterial environment, which allows it to progressively eradicate MRSA populations over time rather than merely inhibiting them statically, thereby preventing resistance development
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles demonstrate significant antibacterial and antifungal activity, maintaining effective concentrations and stability, reducing the risk of resistance development and minimizing side effects, while being easily administered without the need for organic solvents.
Implementation Method 1
forming stable micellar structures that maintain antibacterial activity and stability over time
Data Source
AI summary
Non-vesicular nanoparticles which have antibacterial activity and are made from a C8-C28 fatty acid or a derivative thereof, a surfactant and an optional lipid.